HER2 expression in cervical cancer as a potential therapeutic target

BMC Cancer

Volumn 4, Issue , 2004, Pages

  Chavez Blanco, Alma ^a   Perez Sanchez, Victor ^a   Gonzalez Fierro, Aurora ^a   Vela Chavez, Teresa ^a   Candelaria, Myrna ^a   Cetina, Lucely ^a   Vidal, Silvia ^a   Dueñas Gonzalez, Alfonso ^a  

^a INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG APPROVAL; DRUG TARGETING; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS; PATIENT CARE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; UTERINE CERVIX CANCER; ADENOSQUAMOUS CARCINOMA; CANCER STAGING; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; PATHOLOGY; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; TUMOR RECURRENCE; UTERINE CERVIX TUMOR;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RECEPTOR, ERBB-2; UTERINE CERVICAL NEOPLASMS;

EID: 13144302944     PISSN: 14712407     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2407-4-59     Document Type: Article

References (35)

1. Dueñas-Gonzalez A, Cetina L, Mariscal I, de la Garza J: Modern management of locally advanced cervical carcinoma. Cancer Treat Rev 2003, 29:389-399.
2. Chang JL, Tsao YP, Liu DW, Han CP, Lee WH, Chen SL: The expression of type I growth factor receptors in the squamous neoplastic changes of uterine cervix. Gynecol Oncol 1999, 73:62-71.
3. Horton J: Trastuzumab use in breast cancer: clinical issues. Cancer Control 2002, 9:499-507.
4. Press MF, Hung G, Godolphin W, Slamon DJ: Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994, 54:2771-2777.
5. Menard S, Casalini P, Campiglio M, Pupa S, Agresti R, Tagliabue E: HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer. Ann Oncol 2001, 12(Suppl 1):S15-19.
6. Kristensen GB, Holm R, Abeler VM, Trope CG: Evaluation of the prognostic significance of cathepsin D, epidermal growth factor receptor, and c-erbB-2 in early cervical squamous cell carcinoma. An immunohistochemical study. Cancer 1996, 78:433-440.
7. Oka K, Nakano T, Arai T: c-erbB-2 Oncoprotein expression is associated with poor prognosis in squamous cell carcinoma of the cervix. Cancer 1994, 73:664-671.
8. Kihana T, Tsuda H, Teshima S, Nomoto K, Tsugane S, Sonoda T, Matsuura S, Hirohashi S: Prognostic significance of the overexpression of c-erbB-2 protein in adenocarcinoma of the uterine cervix. Cancer 1994, 73:148-153.
9. Niibe Y, Nakano T, Ohno T, Suzuki Y, Oka K, Tsujii H: Prognostic significance of c-erbB-2/HER2 expression in advanced uterine cervical carcinoma with para-aortic lymph node metastasis treated with radiation therapy. Int J Gynecol Cancer 2003, 13:849-855.
10. Lee JS, Kim HS, Jung JJ, Lee MC, Park CS: Expression of vascular endothelial growth factor in adenocarcinomas of the uterine cervix and its relation to angiogenesis and p53 and c-erbB-2 protein expression. Gynecol Oncol 2002, 85:469-475.
11. Leung TW, Cheung AN, Cheng DK, Wong LC, Ngan HY: Expressions of c-erbB-2, epidermal growth factor receptor and panras proto-oncogenes in adenocarcinoma of the cervix: correlation with clinical prognosis. Oncol Rep 2001, 8:1159-1164.
12. Hove MG, Dinh TV, Hannigan EV, Lucci JA 3rd, Chopra V, Smith ER, To T: Oncogene expression and microvessel count in recurrent and nonrecurrent stage Ib squamous cell carcinoma of the cervix. J Reprod Med 1999, 44:493-496.
13. Nishioka T, West CM, Gupta N, Wilks DP, Hendry JH, Davidson SE, Hunter RD: Prognostic significance of c-erbB-2 protein expression in carcinoma of the cervix treated with radiotherapy. J Cancer Res Clin Oncol 1999, 125:96-100.
14. Kersemaekers AM, Fleuren GJ, Kenter GG, Van den Broek LJ, Uljee SM, Hermans J, Van de Vijver MJ: Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis. Clin Cancer Res 1999, 5:577-586.
15. Scholl S, Beuzeboc P, Pouillart P: Targeting HER2 in other tumor types. Ann Oncol 2001, 12(Suppl 1):S81-87.
16. Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR: Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 2003, 21:283-290.
17. Haddad R, Colevas AD, Krane JF, Cooper D, Glisson B, Amrein PC, Weeks L, Costello R, Posner M: Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol 2003, 39:724-727.
18. Yaziji H, Goldstein LC, Barry TS, Werling R, Hwang H, Ellis GK, Gralow JR, Livingston RB, Gown AM: HER-2 testing in breast cancer using parallel tissue-based methods. JAMA 2004, 291: 972-1977.
19. Fujimura M, Katsumata N, Tsuda H, Uchi N, Miyazaki S, Hidaka T, Sakai M, Saito S: HER2 Is Frequently Over-expressed in Ovarian Clear Cell Adenocarcinoma: Possible Novel Treatment Modality Using Recombinant Monoclonal Antibody against HER2, Trastuzumab. Jpn J Cancer Res 2002, 93:1250-1257.
20. Iwamoto H, Fukasawa H, Honda T, Hirata S, Hoshi K: HER2 expression in ovarian clear cell carcinomas. Int J Gynecol Cancer 2003, 13:28-31.
21. Hirsch FR, Varella-Garcia M, Franklin WA, Veve R, Chen L, Helfrich B, Zeng C, Baron A, Bunn PA Jr: Evaluation of HER2 gene amplification and protein expression in non-small cell lung carcinomas. Br J Cancer 2002, 86:1449-1456.
22. Nathanson DR, Culliford AT 4th, Shia J, Chen B, D'Alessio M, Zeng ZS, Nash GM, Gerald W, Barany F, Paty PB: HER 2/neu expression and gene amplification in colon cancer. Int J Cancer 2003, 105:796-802.
23. Matsuyama S, Kitajima Y, Sumi K, Mori D, Satoh T, Miyazaki K: Gallbladder cancers rarely overexpress HER2, demonstrated by Hercep Test. Oncol Rep 2004, 11:815-819.
24. Potti A, Hille R, Koch M: Immunohistochemical determination of HER2 in malignant melanoma. Anticancer Res 2003, 23(5A):4067-4069.
25. Bellone S, Palmieri M, Gokden M, Joshua J, Roman JJ, Pecorelli S, Cannon MJ, Santin AD: Selection of HER2-positive tumor cells in early stage cervical cancer: implications for Trastuzumab-mediated therapy. Gynecol Oncol 2003, 91: 31-240.
26. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002, 20:719-726.
27. Gatzemeier U, Groth G, Butts C, Van Zandwijk N, Shepherd F, Ardizzoni A, Barton C, Ghahramani P, Hirsh V: Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol 2004, 15: 9-27.
28. Gancberg D, Di Leo A, Cardoso F, Rouas G, Pedrocchi M, Paesmans M, Verhest A, Bernard-Marty C, Piccart MJ, Larsimont D: Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 2002, 13: 036-1043.
29. Eccles SA: The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis. J Mammary Gland Biol Neoplasia 2001, 6:393-406.
30. Knuefermann C, Lu Y, Liu B, Jin W, Liang K, Wu L, Schmidt M, Mills GB, Mendelsohn J, Fan Z: HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 2003, 22:3205-3212.
31. Berchuck A, Rodriguez G, Kamel A, Soper JT, Clarke-Pearson DL, Bast RC Jr: Expression of epidermal growth factor receptor and HER2 in normal and neoplastic cervix, vulva, and vagina. Obstet Gynecol 1990, 76(3 Pt 1):381-387.
32. Mark HF, Feldman D, Das S, Sun CL, Samy M, Lathrop J: HER-2/neu oncogene amplification in cervical cancer studied by fluorescent in situ hybridization. Genet Test 1999, 3: 37-242.
33. Dellas A, Torhorst J, Gaudenz R, Mihatsch MJ, Moch H: DNA copy number changes in cervical adenocarcinoma. Clin Cancer Res 2003, 9:2985-2991.
34. Earp HS, Dawson TL, Li X, Yu H: Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research. Breast Cancer Res Treat 1995, 35:115-32.
35. Hammock L, Lewis M, Phillips C, Cohen C: Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization. Hum Pathol 2003, 34:1043-1047.